Mergers & acquisitions
Innovate Biopharmaceuticals, Inc. and RDD Pharma, Ltd announced that the two companies entered into a definitive merger agreement pursuant to which Innovate agreed to acquire all of the outstanding capital stock of privately-held RDD in exchange for a combination of common and preferred shares.
For the past five years, there have been more than 400 mergers and acquisitions with companies in the gene therapy, immuno-oncology, microbiome and orphan drugs therapeutic space in North America and that trend is likely to continue, according to a new analysis.
Shares of Dova Pharmaceuticals are up more than 38% in premarket trading after Sobi announced its intentions to acquire the company for $915 million.
Companies’ complementary strengths in data and cloud technology to improve healthcare efficiency and patient outcomes
60,000 sq. ft World-class Integrated R&D Facility at TICEL Bio Park to House 250 scientists
OncoCyte, a global oncology diagnostics company, recently announced that it will acquire Razor Genomics, which has developed a novel molecular diagnostic test for early-stage non-small cell lung cancer.
Lundbeck announced the acquisition aimed at eptinezumab, Alder’s investigational monoclonal antibody (mAb) for migraine prevention targeting the calcitonin gene-related peptide that has been submitted to the U.S. Food and Drug Administration for potential approval.
Baxter International Inc., a leading global medical products company, has entered into a definitive agreement to acquire Cheetah Medical, an Israel-based leading provider of non-invasive hemodynamic monitoring technologies with offices in Boston, Massachusetts as well as Tel Aviv, as detailed in the company press release.
Building on its unique six-year relationship with Avalon Ventures, GlaxoSmithKline will acquire San Diego-based Sitari Pharmaceuticals and its transglutaminase 2 small molecule program for celiac disease.
Flexion Therapeutics, Inc. and Xenon Pharmaceuticals Inc. announced that the companies have entered into a definitive agreement that provides Flexion with the global rights to develop and commercialize XEN402, a NaV1.7 inhibitor, for the management of post-operative pain.
PRESS RELEASES